Vor Biopharma (VOR) Stock Price, News & Analysis

Company Overview

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $2.05 to $2.51
• 50-Day Range: $1.43 to $2.67
• 52-Week Range: $0.13 to $3.29
• Volume: 8.22 million shs
• Average Volume: 4.87 million shs
• Market Capitalization: $260.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

VOR Stock Analysis - Frequently Asked Questions

How have VOR shares performed this year?

Vor Biopharma's stock was trading at $1.06 at the beginning of 2025. Since then, VOR shares have increased by 94.3% and is now trading at $2.06.

How were Vor Biopharma's earnings last quarter?

Vor Biopharma Inc. (NASDAQ:VOR) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($2.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $1.61.

When did Vor Biopharma IPO?

Vor Biopharma (VOR) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel acted as the underwriters for the IPO.

How do I buy shares of Vor Biopharma?

Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VOR
• Previous Symbol: NASDAQ:VOR
• CIK: 1817229
• Web: N/A
• Phone: (617) 655-6580
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,683,000
• Free Float: 126,113,000
• Market Cap: $260.97 million
• Optionable: N/A
• Beta: 2.06